NCT02988960 2026-01-09A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsAbbViePhase 1 Active not recruiting163 enrolled
NCT05005403 2025-10-28Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or BevacizumabAbbViePhase 1 Recruiting512 enrolled
NCT06158958 2025-10-27A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid TumorsAbbViePhase 1 Terminated27 enrolled